FIELD: medicine.
SUBSTANCE: invention refers to medicine and molecular biology and can be used for treating breast cancer (BC). Method is carried out by targeted delivery of thallium salts using surface-modified virions of phage MS2, containing cyclic ligand iRGD, having high affinity to integrin avb3 and covalently bonded to the cladding, and a core with genomic RNA with thallium salts.
EFFECT: using the invention enables reducing the tumour size by directing cytotoxic effect on focal and metastatic accumulations of tumour cells.
1 cl, 1 tbl, 2 dwg, 4 ex
| Title | Year | Author | Number |
|---|---|---|---|
| METHOD OF POLY-SIGNAL ACTIVATION OF MALIGNANT SOLID TUMORS CELL APOPTOSIS | 2015 |
|
RU2599462C1 |
| RECTAL SUPPOSITORIES BASED ON MODIFIED BACTERIOPHAGE MS2 FOR TARGETED THERAPY OF MALIGNANT SOLID TUMOURS | 2019 |
|
RU2735828C1 |
| METHOD FOR PRODUCING BACTERIOPHAGE HPV AND METHOD FOR PRODUCING MODIFIED BACTERIOPHAGE HPV | 2022 |
|
RU2790451C1 |
| METHOD OF PRODUCING VIRUS-LIKE BACTERIOPHAGE PARTICLE | 2024 |
|
RU2821694C1 |
| METHOD OF OBTAINING PARTICLES OF BACTERIOPHAGES OF LEVIVIRUS FAMILY | 2020 |
|
RU2811106C2 |
| RGD-(BACTERIO)CHLOROPHYLL CONJUGATES FOR PHOTODYNAMIC THERAPY AND NECROTIC TUMOUR IMAGING | 2009 |
|
RU2518296C2 |
| RECOMBINANT PLASMID pET-15b_T3_RL DNA PROVIDING SYNTHESIS OF RECOMBINANT FUSION PROTEIN CONSISTING OF TUMOR-SPECIFIC PEPTIDES AND ANTITUMOR PEPTIDE RL2, AND RECOMBINANT FUSION PROTEIN POSSESSING ANTI-TUMOR ACTIVITY AGAINST HUMAN BREAST CANCER | 2016 |
|
RU2619053C1 |
| RECEPTOR TARGETING CONSTRUCTS AND USES THEREOF | 2015 |
|
RU2682335C2 |
| METHODS AND COMPOSITIONS FOR CAR-T-CELL THERAPY | 2017 |
|
RU2792653C2 |
| RGD-CONTAINING PEPTIDOMIMETICS AND THEIR APPLICATION | 2009 |
|
RU2519736C2 |
